



SGLT2i Effect on Atrial Fibrillation: A Network Meta-analysis of Randomized Controlled Trials

Mariani MV, et al. Journal of Cardiovascular Electrophysiology. 2024

- Gliflozins are recommended as first-line treatment in patients with heart failure and/or cardiovascular comorbidities as they have been shown to decrease the occurrence of atrial fibrillation (AF).
- Fifty-nine studies were included in the meta-analysis involving 108 026 patients, of whom 60 097 received gliflozins and 47 929 received placebo.
- Gliflozins provided a statistically significant reduction of AF occurrence relative to standard of care therapy in the overall population and in patients with diabetes and cardiorenal diseases.
- Dapagliflozin significantly decreased AF occurrence as compared to placebo ($p < .0001$) in the overall population, patients with diabetes ($p = 0.0345$), diabetes associated with cardiorenal diseases ($p = .0063$) and studies with follow-up ≥ 1 year.

Dapagliflozin significantly reduced AF risk in the overall population and diabetes patients, while other gliflozins did not significantly decrease AF occurrence.

